Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors

ATR Inhibition Broadly Sensitizes Ovarian Cancer Cells to Chemotherapy Independent of BRCA Status

(2013) C. J. Huntoon et al.   CANCER RESEARCH

Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity

(2013) I. Bajrami et al.   CANCER RESEARCH

The Exomes of the NCI-60 Panel: A Genomic Resource for Cancer Biology and Systems Pharmacology

(2013) O. D. Abaan et al.   CANCER RESEARCH

BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation

(2013) Britta Stordal et al.   Molecular Oncology

RNF8 Regulates Assembly of RAD51 at DNA Double-Strand Breaks in the Absence of BRCA1 and 53BP1

(2012) S. Nakada et al.   CANCER RESEARCH

The cyclin K/Cdk12 complex

(2012) Dalibor Blazek   CELL CYCLE

Poly (ADP-ribose) polymerase inhibitors

(2012) Elena S. Ratner et al.   CURRENT OPINION IN ONCOLOGY

Interaction of Cyclin-Dependent Kinase 12/CrkRS with Cyclin K1 Is Required for the Phosphorylation of the C-Terminal Domain of RNA Polymerase II

(2012) S.- W. G. Cheng et al.   MOLECULAR AND CELLULAR BIOLOGY

Absolute quantification of somatic DNA alterations in human cancer

(2012) Scott L Carter et al.   NATURE BIOTECHNOLOGY

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

(2012) Jonathan Ledermann et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes

(2011) D. Blazek et al.   GENES & DEVELOPMENT

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

Unraveling the mechanism of BRCA2 in homologous recombination

(2011) William K Holloman   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Heat Shock Protein 90 Inhibition Depletes LATS1 and LATS2, Two Regulators of the Mammalian Hippo Tumor Suppressor Pathway

(2010) C. J. Huntoon et al.   CANCER RESEARCH

CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1

(2010) B. Bartkowiak et al.   GENES & DEVELOPMENT

Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer

(2010) Bryan T.J. Hennessy et al.   JOURNAL OF CLINICAL ONCOLOGY

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval

(2010) Peter C. Fong et al.   JOURNAL OF CLINICAL ONCOLOGY

Personalizing Therapy for Ovarian Cancer:BRCAness and Beyond

(2010) Robert C. Bast et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

(2010) M William Audeh et al.   LANCET

Making the best of PARP inhibitors in ovarian cancer

(2010) Susana Banerjee et al.   Nature Reviews Clinical Oncology

Cisplatin-Induced DNA Damage Activates Replication Checkpoint Signaling Components that Differentially Affect Tumor Cell Survival

(2009) J. M. Wagner et al.   MOLECULAR PHARMACOLOGY

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

The multi-tasking P-TEFb complex

(2008) Vanessa Brès et al.   CURRENT OPINION IN CELL BIOLOGY

DNA repair deficiency as a therapeutic target in cancer

(2008) Sarah A Martin et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Phosphatase PPM1A Regulates Phosphorylation of Thr-186 in the Cdk9 T-loop

(2008) Yan Wang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY